| 000 | 01653 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513214709.0 | ||
| 264 | 0 | _c20000926 | |
| 008 | 200009s 0 0 eng d | ||
| 022 | _a0022-1899 | ||
| 024 | 7 |
_a10.1086/315720 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPolyak, S J | |
| 245 | 0 | 0 |
_aThe protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. _h[electronic resource] |
| 260 |
_bThe Journal of infectious diseases _cAug 2000 |
||
| 300 |
_a397-404 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAmino Acid Sequence |
| 650 | 0 | 4 | _aBinding Sites |
| 650 | 0 | 4 | _aConserved Sequence |
| 650 | 0 | 4 |
_aEukaryotic Initiation Factor-2 _xmetabolism |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aGlycoproteins _xgenetics |
| 650 | 0 | 4 |
_aHepacivirus _xgenetics |
| 650 | 0 | 4 |
_aHepatitis C _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferons _xtherapeutic use |
| 650 | 0 | 4 | _aPhosphorylation |
| 650 | 0 | 4 | _aProtein Binding |
| 650 | 0 | 4 | _aProtein Structure, Tertiary |
| 650 | 0 | 4 | _aSequence Homology, Amino Acid |
| 650 | 0 | 4 |
_aViral Envelope Proteins _xgenetics |
| 650 | 0 | 4 |
_aeIF-2 Kinase _xantagonists & inhibitors |
| 700 | 1 | _aNousbaum, J B | |
| 700 | 1 | _aLarson, A M | |
| 700 | 1 | _aCotler, S | |
| 700 | 1 | _aCarithers, R L | |
| 700 | 1 | _aGretch, D R | |
| 773 | 0 |
_tThe Journal of infectious diseases _gvol. 182 _gno. 2 _gp. 397-404 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1086/315720 _zAvailable from publisher's website |
| 999 |
_c10864785 _d10864785 |
||